Aldurazyme (laronidase) for an Omani family: what the pathway looks like in 2026
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
Omani families looking into Aldurazyme for a child with mucopolysaccharidosis type I, MPS I, are in a workable position. The therapy has a long track record in the region. Oman Directorate General of Pharmaceutical Affairs and Drug Control (DGPADC) operates a mature pharmaceutical regulatory framework. Royal Hospital Muscat and Oman Defence Force Hospital handle the initial workup and the ongoing surveillance. For severe Hurler patients needing HSCT, cross-border BMT-centre referrals to KFSHRC Riyadh, to Saudi German Hospital networks, or to international centres of excellence are operationally familiar to the Omani medical community.
This page is meant to be the first honest read you get on Aldurazyme in Oman, written by the team that would coordinate around your child's case if you decided you wanted operational support on the workup, the MoH treatment-abroad documentation (if applicable), the cross-border logistics, or the long-term cost picture.
We will be specific about MPS I, what the workup decides, the regulatory pathway, the cost in OMR and US dollars, the cross-border infusion patterns, and where Reserve Meds adds value.
What MPS I actually is, in plain terms
MPS I is a lysosomal storage disorder caused by deficiency of the enzyme alpha-L-iduronidase (IDUA). The deficiency leads to progressive accumulation of dermatan sulfate and heparan sulfate in lysosomes across the body. Presentation spans a clinical spectrum: severe Hurler with infant-onset multisystemic disease and progressive cognitive decline, intermediate Hurler-Scheie with somatic features but preserved cognition, and attenuated Scheie often diagnosed in adolescence or adulthood.
Aldurazyme is recombinant alpha-L-iduronidase, administered as a weekly intravenous infusion at 0.58 mg/kg over 3 to 4 hours. The therapy is disease-modifying for non-CNS manifestations. It does not cross the blood-brain barrier and does not address the cognitive decline of severe Hurler.
For severe Hurler infants, the standard of care is hematopoietic stem cell transplantation, HSCT, ideally before age 2 to 2.5. Aldurazyme is used as a bridge to HSCT and often as an adjunct afterwards. For Hurler-Scheie and Scheie patients, ERT alone is typically the long-term answer.
The workup that decides eligibility
The workup has five components: urinary GAG screen, alpha-L-iduronidase enzyme activity assay (the definitive enzymatic confirmation), IDUA gene sequencing for severity classification, baseline organ assessments (echocardiogram, FVC, sleep study, ophthalmology, ENT, hepatomegaly, joint range of motion, 6-minute walk test), and severity classification by the metabolic specialist.
In Oman, the workup typically begins at Royal Hospital Muscat, the public-sector tertiary referral centre for paediatric metabolic and genetic conditions; Sultan Qaboos University Hospital (SQUH), the academic medical centre with paediatric and adult metabolic services; and the National Genetic Centre, which coordinates inborn-error-of-metabolism screening and confirmatory enzymatic and molecular testing. Onward referral to the receiving haematology and BMT services occurs for severe Hurler infants in whom HSCT is planned.
The DGPADC named-patient pathway in Oman
Aldurazyme is on the radar of the Directorate General of Pharmaceutical Affairs and Drug Control (DGPADC) and is supplied to confirmed MPS I cases through the personal-use named-patient import authorisation pathway under Royal Decree 35/2015. The treating paediatric metabolic specialist at Royal Hospital Muscat or SQUH files the prescription and clinical justification documenting the enzymatic and genetic confirmation, the severity classification, the baseline organ profile, and the proposed weekly infusion plan. The DGPADC reviews and on approval issues an import permit. Reserve Meds operates as the US-side coordinator, sourcing Aldurazyme through a DSCSA-compliant specialty wholesaler and coordinating validated cold-chain logistics at 2 to 8 degrees Celsius.
Documentation required
A complete filing includes the prescription nami
Regulatory status of Aldurazyme (laronidase) in Oman, 2026
Aldurazyme (laronidase) is approved by the US Food and Drug Administration for the labelled indication of enzyme replacement therapy for mucopolysaccharidosis I (MPS I) (see the FDA approval record at accessdata.fda.gov). The European Medicines Agency holds a parallel marketing authorisation where applicable (see the EMA EPAR at ema.europa.eu). For a Oman-based patient, the access pathway runs through the Ministry of Health (MoH) Directorate General of Pharmaceutical Affairs and Drug Control framework. The official regulator portal is at www.moh.gov.om; the locally registered medicines list is at www.moh.gov.om/en/services/medicine-licensing.
Where Aldurazyme (laronidase) is held on the locally registered list at the time the case opens, standard prescription and in-country dispensing applies and the treating consultant at the prescribing tertiary centre coordinates supply through the institutional pharmacy. Where Aldurazyme (laronidase) is not yet on the locally registered list at the time the case opens, the named-patient and personal-import framework that the Ministry of Health (MoH) Directorate General of Pharmaceutical Affairs and Drug Control maintains for reference-authority-approved medicines is the operative route. The qualifying conditions are well established: the medicine is approved by a recognised reference authority (FDA or EMA qualifies), no locally available alternative is clinically equivalent for the specific patient indication, the treating physician of record takes documented clinical responsibility, and chain of custody is preserved end to end from the US source through international transit to the named dispensing facility. Confirm current registration status at intake; the published registration list governs.
Tertiary centers and clinical coordination in Oman
The Oman tertiary referral network for a Aldurazyme (laronidase) case is concentrated at Sultan Qaboos University Hospital (SQUH), The Royal Hospital Muscat, Sultan Qaboos Comprehensive Cancer Care and Research Centre, and Khoula Hospital. These centers carry the haematology, oncology, neurology, metabolic, infectious-disease, or rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For enzyme replacement therapy (ERT) therapies that require specialised infusion infrastructure, baseline organ-function workup, or post-treatment monitoring of a complexity beyond what a community centre is configured for, the case is routinely referred to one of these tertiary centers from the outset.
For oral, subcutaneous, or in-clinic infusion therapies that can be administered in Oman once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Reserve Meds handles US-side sourcing under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, international shipment to the named dispensing facility, and re-supply cadence aligned to the dosing schedule. For therapies that require US-certified treatment center administration (some cell, gene, and complex biologics fall in this bucket), the practical access pathway runs through patient travel to a US-certified treatment center rather than import into Oman; the Oman tertiary team continues to handle upstream referral package assembly and the long-term follow-up after the patient returns home.
Oman pricing reference and payer posture, 2026
Reserve Meds publishes a drug-only US cash-pay reference range at intake and issues a delivered, itemised quote within 24 hours once the treating physician's documentation is in. The 2026 reference rate used for OMR conversion is 1 USD = 0.385 OMR. As an illustrative composite case in the 2026 reference band, the US cash-pay drug-only cost for Aldurazyme (laronidase) reflects the US wholesale acquisition cost published by the manufacturer (Sanofi (originating partnership with BioMarin)) plus standard specialty pharmacy markup; the precise band is delivered in the case quote because it varies by indication, dosing, and pack size.
Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, Reserve Meds concierge coordination, and any patient and caregiver travel and accommodation are itemised separately. For a complex case the total course cost commonly lands meaningfully above the drug-only band once treatment-centre fees, pre-treatment workup, on-treatment monitoring, complication management, and family logistics are added in.
Payer posture in Oman is overwhelmingly cash-pay for named-patient imports and cross-border specialty cases. The relevant public-payer body is MoH public-sector coverage for Omani nationals; commercial insurance via DhofarInsurance, AXA Gulf, NLGI Oman; the portal is at www.moh.gov.om. Public coverage generally does not extend to non-locally-registered specialty cases. Private health insurance plans review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake.
Access barriers and how Reserve Meds clears them
The five access barriers we see most often for a Aldurazyme (laronidase) case in Oman are: (1) Regulatory documentation complexity. The Ministry of Health (MoH) Directorate General of Pharmaceutical Affairs and Drug Control named-patient and personal-import application package requires a specific bundle (physician clinical rationale letter, prescription, patient identifier, product strength and quantity, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent for the patient). Reserve Meds provides physician-facing templates that match the format reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with our US-licensed specialty wholesale partners to secure Aldurazyme (laronidase) from authorised distribution under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.
(3) Clinical eligibility documentation. The treating consultant at the prescribing tertiary centre defines eligibility against the FDA labelled indication and the relevant clinical-practice guideline; Reserve Meds does not adjudicate the clinical decision. (4) Family logistics. Patient and caregiver travel where applicable, accommodation near the treatment center where applicable, in-country transport, translator support where needed, and post-treatment data flow back to the treating Oman physician are coordinated as a single arc. (5) Insurance and payer posture. Cash-pay is the default. Where private insurance review is contemplated, we supply documentation for the family's submission but we do not bill insurers and we do not adjudicate insurance disputes.
Drug-specific clinical context for Aldurazyme (laronidase): the labelled indication is enzyme replacement therapy for mucopolysaccharidosis I (MPS I). The enzyme replacement therapy (ERT) mechanism shapes both the eligibility workup and the monitoring schedule. The relevant clinical-practice guideline body is MPS I International Consensus Panel and the European MPS Network at www.ncbi.nlm.nih.gov/pmc/articles/PMC2754327/. The treating physician of record makes the clinical decision; Reserve Meds is the coordination layer that clears the operational and regulatory barriers between the prescription and the delivered course.
Recent regulatory and access news for Aldurazyme (laronidase) in Oman, 2026
The Ministry of Health (MoH) Directorate General of Pharmaceutical Affairs and Drug Control portal at www.moh.gov.om and the locally registered medicines list at www.moh.gov.om/en/services/medicine-licensing are the authoritative source for the current Oman listing status of Aldurazyme (laronidase); the snapshot date governs. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages are the authoritative sources for any active Aldurazyme (laronidase) safety advisory or shortage signal over the most recent 12-month window. The FDA labelled indication for Aldurazyme (laronidase) remains enzyme replacement therapy for mucopolysaccharidosis I (MPS I) (see the current FDA approval record at accessdata.fda.gov). Sanofi (originating partnership with BioMarin) continues commercial supply per the FDA-labelled indication and the EMA marketing authorisation. The MPS I International Consensus Panel and the European MPS Network guidance at www.ncbi.nlm.nih.gov/pmc/articles/PMC2754327/ remains the relevant clinical-practice reference. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.